Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02788916
Other study ID # Brentuximab-5012
Secondary ID TAK-HEM-2015-01
Status Completed
Phase N/A
First received May 23, 2016
Last updated March 17, 2017
Start date September 25, 2015
Est. completion date January 12, 2017

Study information

Verified date March 2017
Source Takeda
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to establish the distribution of peripheral T-cell lymphocyte (PTCL) subtypes by re-analysis and re-classification of samples according to the 2008 World Health Organization (WHO) classification of lymphoid neoplasms.


Description:

This study is a retrospective, non-interventional and, post-authorization observational study of other designs (PAS-OD).

This multicenter trial will be conducted in Spain. Retrospective review of medical records and initial tumor biopsies of participants diagnosed with PTCL in the period of 6 years between 01/01/2008 and 31/12/2013 will be performed. Initial tumor biopsies and histological preparations, filed and previously anonymized, will be sent to the central laboratory for assessment.


Recruitment information / eligibility

Status Completed
Enrollment 198
Est. completion date January 12, 2017
Est. primary completion date November 10, 2016
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- Participants diagnosed with PTCL in the six years between 01/01/2008 and 31/12/2013.

- Availability of initial tumor biopsy diagnosis in paraffin block (node or core biopsy of 16-18mm).

- PTCL subtypes permitted by WHO 2008 classification of lymphoid neoplasms:

- Natural killer/ T-lymphocytes (NK /T-cell) lymphoma extranodal nasal type

- Enteropathic T-cell lymphoma

- Hepatosplenic T-cell lymphoma

- Peripheral T-cell lymphoma, not otherwise specified

- Angioimmunoblastic T-cell lymphoma

- Anaplastic large cell lymphoma, Anaplastic lymphoma kinase positive (ALK)+

- Anaplastic large cell lymphoma, ALK-

Exclusion Criteria:

• Participants with an unavailable history (lost, empty or not recoverable).

Study Design


Related Conditions & MeSH terms


Intervention

Other:
No Intervention


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Takeda

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Distribution of Peripheral T-cell Lymphoma (PTCL) Subtypes Distribution of PTCL subtypes by re-analysis and re-classification of samples according to the 2008 WHO classification of lymphoid neoplasms will be estimated. Up to 6 months
Secondary Percentage of Participants with Each Subtypes of PTCL Percentage of participants with each subtypes of PTCL according to the WHO 2008 classification of lymphoid neoplasms will be reported. Up to 6 months
Secondary Rate of Discrepancy Between the Initial Diagnosis and Re-analysis and Re-classification Rate of discrepancy between the initial diagnosis of PTCL in participants and diagnosis by re-analysis and re-classification according to the WHO 2008 classification will be determined. Up to 6 months
Secondary Expression of Cluster of Differentiation 30 (CD30) by Immunohistochemistry and Quantitative Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) in Different Subtypes of PTCL Expression of CD30 by immunohistochemistry and quantitative RT-PCR in different subtypes of PTCL will be determined. Up to 6 months
Secondary Correlation Between the Expression of CD30 and Lymphoid Lineage Markers of T and B cells will be used in order to determine if CD30 expression occurs in tumor cells or other B-lineage. Up to 6 months
Secondary Correlation Between the Expression of CD30, Prognostic Indices Used In PTCL and Survival Survival includes progression free survival: period from date of start of treatment until tumor progression or death, whichever occurs first. Overall survival: period from date of diagnosis to the date of death. Up to 6 months
Secondary Classification of Peripheral T-cell Lymphoma The PTCL is classified according to the expression of CD30 and T-Cell Receptor ß (TCRß) and T-Cell Receptor ? (TCR?) by immunohistochemistry (IHC). Up to 6 months
Secondary T-cell Clonality in PTCL Analysis of T-cell clonality in PTCL will be performed. Clonality defines the profile of gene rearrangement of T cell receptor and allow establishing whether proliferation is monoclonal. Up to 6 months
Secondary Correlation Between Most frequent Mutations and Clinical, Phenotypic Factors Distribution of the most frequent mutations in tumors and its correlation with clinical and phenotypic factors will be determined. Up to 6 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03547700 - Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL) Phase 1/Phase 2
Completed NCT02567656 - Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma Phase 1
Completed NCT01142674 - T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma
Withdrawn NCT03355768 - Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL Phase 3
Not yet recruiting NCT05006664 - Brentuximab Vedotin in Combination With CHEP in Patient With PTCL Phase 2
Terminated NCT00514722 - Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies N/A
Completed NCT01679860 - Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma Phase 2
Recruiting NCT06254495 - A Safety Study of SGN-35C in Adults With Advanced Cancers Phase 1
Completed NCT05137847 - A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)
Terminated NCT03601819 - Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders Phase 1
Completed NCT03049449 - T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas Phase 1
Completed NCT00211185 - A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma Phase 2
Not yet recruiting NCT03051581 - 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell Lymphoma N/A
Not yet recruiting NCT03051568 - Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Peripheral T-cell Lymphoma N/A
Completed NCT00646854 - Alemtuzumab and CHOP in T-cell Lymphoma Phase 3
Terminated NCT02535247 - Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma Phase 1/Phase 2
Recruiting NCT02364466 - Cohort of Peripheral T Cell Lymphoma N/A
Recruiting NCT02404571 - GDP in Frontline Chemotherapy for Patients With PTCL-NOS Phase 2
Completed NCT03742921 - ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma
Completed NCT02181218 - Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas Phase 1